Metformin is the first-line drug for treatment of type 2 diabetes mellitus (T2DM) and is effective in decreasing plasma glucose levels. This review summarizes the glucoregulatory mechanisms of metformin in T2DM and highlights emerging evidence that metformin decreases obesity-induced meta-inflammation and acts in the gastrointestinal tract.
- Marc Foretz
- Bruno Guigas
- Benoit Viollet
